Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $19.5 million.

  • Immunome's Non-Current Assets rose 51.29% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 51.29%. This contributed to the annual value of $18.9 million for FY2024, which is 392.62% up from last year.
  • As of Q3 2025, Immunome's Non-Current Assets stood at $19.5 million, which was up 3.16% from $18.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Non-Current Assets peaked at $19.6 million during Q1 2025, and registered a low of $1.6 million during Q1 2023.
  • In the last 3 years, Immunome's Non-Current Assets had a median value of $11.9 million in 2024 and averaged $10.6 million.
  • Data for Immunome's Non-Current Assets shows a peak YoY soared of 636.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunome's Non-Current Assets stood at $3.8 million in 2023, then soared by 392.62% to $18.9 million in 2024, then soared by 51.29% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $18.9 million for Q2 2025, and $19.6 million during Q1 2025.